BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:BIO • US0905722072
301.5 USD
+1.96 (+0.65%)
At close: Feb 6, 2026
303.97 USD
+2.47 (+0.82%)
After Hours: 2/6/2026, 8:19:37 PM
Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 58 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year BIO was profitable.
- BIO had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
- In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
- With a Return On Assets value of -6.97%, BIO perfoms like the industry average, outperforming 51.72% of the companies in the same industry.
- BIO has a Return On Equity (-10.03%) which is comparable to the rest of the industry.
- BIO's Return On Invested Capital of 2.26% is fine compared to the rest of the industry. BIO outperforms 60.34% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 13.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- BIO has a better Operating Margin (10.27%) than 68.97% of its industry peers.
- BIO's Operating Margin has been stable in the last couple of years.
- The Gross Margin of BIO (52.42%) is better than 62.07% of its industry peers.
- BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- BIO has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, BIO has less shares outstanding
- Compared to 1 year ago, BIO has a worse debt to assets ratio.
2.2 Solvency
- BIO has an Altman-Z score of 3.37. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
- BIO has a Altman-Z score of 3.37. This is in the better half of the industry: BIO outperforms 68.97% of its industry peers.
- The Debt to FCF ratio of BIO is 3.57, which is a good value as it means it would take BIO, 3.57 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.57, BIO is in the better half of the industry, outperforming 75.86% of the companies in the same industry.
- BIO has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
- BIO's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. BIO outperforms 56.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.37 |
ROIC/WACC0.21
WACC10.75%
2.3 Liquidity
- BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of BIO (5.44) is better than 84.48% of its industry peers.
- BIO has a Quick Ratio of 3.94. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 3.94, BIO is doing good in the industry, outperforming 67.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- The earnings per share for BIO have decreased by -1.90% in the last year.
- BIO shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
- The Revenue has decreased by -0.88% in the past year.
- Measured over the past years, BIO shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
- Based on estimates for the next years, BIO will show a decrease in Earnings Per Share. The EPS will decrease by -2.66% on average per year.
- BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.26% yearly.
EPS Next Y-2.48%
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
EPS Next 5Y-2.66%
Revenue Next Year0.04%
Revenue Next 2Y1.13%
Revenue Next 3Y1.96%
Revenue Next 5Y1.26%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 29.24, BIO can be considered very expensive at the moment.
- BIO's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 67.24% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.93, BIO is valued at the same level.
- Based on the Price/Forward Earnings ratio of 29.41, the valuation of BIO can be described as expensive.
- BIO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 67.24% of the companies in the same industry.
- BIO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.24 | ||
| Fwd PE | 29.41 |
4.2 Price Multiples
- 77.59% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.15 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.73
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
5. Dividend
5.1 Amount
- No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
301.5
+1.96 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-12 2026-02-12/amc
Inst Owners92.92%
Inst Owner Change-0.17%
Ins Owners8.18%
Ins Owner Change0%
Market Cap8.13B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (20.1%)
Short Float %4.33%
Short Ratio4.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)14.15%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-4.14%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)-0.65%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.24 | ||
| Fwd PE | 29.41 | ||
| P/S | 3.18 | ||
| P/FCF | 24.15 | ||
| P/OCF | 16.54 | ||
| P/B | 1.21 | ||
| P/tB | 1.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.42%
EPS(NY)10.25
Fwd EY3.4%
FCF(TTM)12.48
FCFY4.14%
OCF(TTM)18.22
OCFY6.04%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.73
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.37 |
F-Score5
WACC10.75%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-2.48%
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.04%
Revenue Next 2Y1.13%
Revenue Next 3Y1.96%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.36%
EBIT Next 3Y14.58%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -2.48% in the next year.